Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other neoplasm 1

Conditions

Precancerous Conditions 32Lymphoma 13Precursor Cell Lymphoblastic Leukemia-Lymphoma 12Lymphoma, Non-Hodgkin 12Lymphoma, Mantle-Cell 12Lymphoma, Large-Cell, Immunoblastic 12Lymphoma, Large B-Cell, Diffuse 12Lymphoma, Follicular 12Leukemia, Lymphocytic, Chronic, B-Cell 12Leukemia 12Burkitt Lymphoma 12Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 11Neoplasms, Plasma Cell 11Multiple Myeloma 11Monoclonal Gammopathy of Undetermined Significance 11Lymphoma, B-Cell, Marginal Zone 11Leukemia, Large Granular Lymphocytic 11Leukemia, Hairy Cell 11Immunoglobulin Light-chain Amyloidosis 11Waldenstrom Macroglobulinemia 10Thrombocythemia, Essential 10Primary Myelofibrosis 10Myeloproliferative Disorders 10Myelodysplastic Syndromes 10Leukemia, Myeloid, Acute 10Immunoblastic Lymphadenopathy 10Hodgkin Disease 10Polycythemia Vera 9Lymphoma, Large-Cell, Anaplastic 9Leukemia, Prolymphocytic 9

Interventions

toripalimab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Primary Condition: Advanced Tumors × Other neoplasm × Clear all
NCT05650203 2023-04-05

A Study of JS009 Monotherapy and JS009 as a Triple Combination Therapy in Patients With Advanced Malignancies

Shanghai Junshi Bioscience Co., Ltd.

Phase 1 Withdrawn
Other neoplasm

Primary Condition: Advanced Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡